Faster global financial news!
Exelixis (EXEL) stock dropped after FDA delayed potential approval of its new colon cancer treatment by three months
Exelixis (EXEL) stock dropped out of a buy zone Friday after the Food and Drug Administration delayed the potential approval of its new colon cancer treatment by three months. The combination includes Exelixis' zanzalintinib and Roche's (RHHBY) Tecentriq. William Blair analyst Andy Hsieh says it's unlikely the agency will outright reject the combo.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Source：Yahoo财经 · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
NOBI Token Value Analysis: Platform Transformation and Token Status
-
2
Databricks Chief Revenue Officer Ron Gabrisko stated that the company's annual recurring revenue (ARR) has grown from less than $1 million to over $7 billion, with approximately $1.7 billion of that coming from AI-related revenue.
-
3
IEA Says Ukraine Strikes Degrade Russian Oil-Refining Industry, With Sanctions Preventing Recovery from Drone Attacks
-
4
Bridgewater Associates Co-CIO Greg Jensen Compares Current AI Moment to February 2020
-
5
Anthropic Warns AI Could Be Used for Bioweapons, Has Blocked Several Related Attempts
-
6
Indonesian Builder PT PP to Restructure $1 Billion Bank Loans
-
7
Neko Health CEO Hjalmar Nilsonne predicts AI and personalized medicine could help people live longer
-
8
a16z Partner: AI is pushing the "power law distribution" of tech investments to the extreme, traditional SaaS faces the risk of being abandoned by the era.
-
9
AMB Coin: Founder, Project Evolution, and Current Price Analysis
-
10
Meta FPS (MFPS) Token Status: Trading Market and Project Background Analysis
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
